XVIVO has received approval from the Swedish MPA to begin clinical studies with the company's new products for heart preservation
XVIVO has received approval from the Swedish Medical Products Agency (MPA) to begin the clinical study with XVIVO's heart preservation products. This means that the study can be started in Sweden and that applications to the other EU countries that will participate in the study can be submitted to the national ethics committees.XVIVO's heart preservation study is a randomized study planned to include eight centers in seven European countries and comprises a total of 138 patients (69 + 69 patients). The aim of the study is to clinically show that the technology is safe and improves the